Globally, breast cancer is one of the most widespread malignancies among women, posing a significant Healthcare challenge that necessitates a comprehensive treatment approach. This paper explores the potential of phytochemicals as therapeutic agents for breast cancer, focusing on their extraction processes, bioavailability challenges, and advancements in drug delivery systems. Phytochemicals, which originate from natural sources, exhibit remarkable bioactivity and can modulate various biochemical pathways involved in cancer progression, making them potential adjuncts or alternatives to conventional therapies. While over 100 phytochemicals with anticancer properties have been identified, only ten have progressed to clinical trials. This limited progress is largely due to challenges in identifying, extracting, and isolating bioactive compounds from crude extracts. Employing in silico approaches alongside advanced extraction technologies can significantly reduce the time required to identify and isolate the therapeutic compounds. However, the therapeutic application of phytochemicals remains constrained by issues such as low solubility, poor absorption, and inadequate tissue penetration. To overcome these limitations, innovative drug delivery systems—particularly nanoparticle-based technologies—are being developed to improve the solubility, bioavailability, and targeted delivery of these compounds. Leveraging advanced delivery methods and maximizing the therapeutic potential of plant-derived bioactive compounds could significantly contribute to the development of effective and sustainable breast cancer treatments.

Monoclonal antibodies (mAbs) have revolutionized therapeutic strategies across a broad spectrum of diseases, yet their efficacy remains constrained by challenges such as suboptimal tumor penetration and insufficient cytotoxicity. This study pioneers an integrative approach, harnessing the untapped potential of plant-derived glycosides and innovative biotechnological advances to redefine mAb efficacy. Specifically, we investigate the novel application of beta-glucan analogs engineered for enhanced immunomodulatory effects, targeting not only malignant cells but also the tumor microenvironment to optimize mAb penetration. Moreover, we introduce a groundbreaking strategy in antibody-drug conjugates (ADCs) by leveraging previously unexploited natural toxins, such as modified saporin variants, which are bioengineered to achieve selective cytotoxicity with minimal off-target effects. This novel ADC formulation is further optimized through the use of nanoencapsulation techniques, ensuring precise delivery and controlled release within the tumor milieu. The research also focuses on hybrid expression systems, scalable mAb production, nanoencapsulation for targeted delivery, and the integration of natural and synthetic techniques for improved antibody therapies. By combining plant-based expression systems with synthetic biology tools, creating a hybrid platform that surpasses traditional plant or mammalian systems in both yield and safety. This approach not only reduces production costs but also introduces a scalable method for the rapid adaptation of mAbs in response to emerging pathogens or tumor mutations. This study opens new avenues by blending natural and synthetic methodologies, ultimately enhancing the therapeutic outcomes of mAbs across various disease states. It underscores the transformative potential of integrating cutting-edge technologies with natural compounds, paving the way for more effective, targeted, and adaptable antibody-based therapies.

In this study, the silver nanoparticles have been green synthesized using C.fenestratum. Synthesized silver nanoparticles have been preliminary validated by the color change to rusty brown from greenish yellow and UV spectroscopy. Morphological analysis through FE-SEM showed cubic and spherical shape of synthesized nanoparticles and the diameter of the synthesized nanoparticles range from 30.18 to 184.89nm.The (EDS) energy-dispersive x-ray spectroscopy spectrum has confirmed the synthesis of AgNPs .The peaks around 400 cm ?1to 600 cm ?1in the IR spectrum indicated the vibration of metals- oxygen (Ag-O), whereas band at 1365.60 cm ?1 and 1357.89 cm ?1 shows the hydroxyl group bending which confirms the synthesis of nanoparticles. The silver nanoparticles exhibited antibacterial activity against E.coli with 20±0.3 mm (Zone of inhibition).